Q2 EPS Estimates for Legend Biotech Reduced by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Analysts at HC Wainwright decreased their Q2 2026 earnings estimates for Legend Biotech in a research note issued on Wednesday, April 15th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of $0.03 for the quarter, down from their prior forecast of $0.06. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s Q3 2026 earnings at $0.07 EPS, Q1 2027 earnings at $0.17 EPS, Q2 2027 earnings at $0.24 EPS and Q4 2027 earnings at $0.43 EPS.

LEGN has been the subject of several other reports. Rothschild & Co Redburn downgraded Legend Biotech from a “buy” rating to a “neutral” rating and set a $24.00 target price for the company. in a research note on Thursday, February 12th. Jefferies Financial Group restated a “buy” rating and issued a $69.00 price target on shares of Legend Biotech in a research note on Tuesday, March 10th. Raymond James Financial reaffirmed an “outperform” rating on shares of Legend Biotech in a report on Monday, February 23rd. Morgan Stanley reduced their price objective on shares of Legend Biotech from $50.00 to $49.00 and set an “overweight” rating for the company in a research report on Wednesday, March 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Legend Biotech in a report on Monday, December 29th. Eleven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Legend Biotech currently has a consensus rating of “Moderate Buy” and an average price target of $58.31.

Legend Biotech Stock Up 2.7%

Shares of NASDAQ LEGN opened at $21.08 on Thursday. The business’s 50 day moving average price is $18.42 and its two-hundred day moving average price is $23.61. The company has a market cap of $3.90 billion, a PE ratio of -26.35 and a beta of 0.08. Legend Biotech has a twelve month low of $16.24 and a twelve month high of $45.30.

Legend Biotech (NASDAQ:LEGN) last issued its earnings results on Wednesday, March 11th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.18. Legend Biotech had a negative net margin of 28.86% and a negative return on equity of 21.93%. The company had revenue of $306.30 million for the quarter, compared to analysts’ expectations of $310.21 million. During the same period in the prior year, the firm earned $0.07 EPS. Legend Biotech’s quarterly revenue was up 64.2% compared to the same quarter last year.

Institutional Trading of Legend Biotech

Several institutional investors have recently added to or reduced their stakes in LEGN. Rakuten Investment Management Inc. acquired a new stake in shares of Legend Biotech during the third quarter worth $7,581,000. Mutual of America Capital Management LLC bought a new stake in shares of Legend Biotech in the third quarter valued at about $2,691,000. SG Americas Securities LLC grew its stake in shares of Legend Biotech by 6,774.9% in the fourth quarter. SG Americas Securities LLC now owns 371,728 shares of the company’s stock valued at $8,081,000 after acquiring an additional 366,321 shares in the last quarter. Artisan Partners Limited Partnership grew its stake in shares of Legend Biotech by 20.1% in the third quarter. Artisan Partners Limited Partnership now owns 2,547,952 shares of the company’s stock valued at $83,089,000 after acquiring an additional 425,684 shares in the last quarter. Finally, Connective Portfolio Management LLC bought a new position in Legend Biotech during the third quarter worth about $805,000. 70.89% of the stock is currently owned by institutional investors.

Insider Activity at Legend Biotech

In other news, CEO Ying Huang sold 9,936 shares of the company’s stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $8.77, for a total value of $87,138.72. Following the transaction, the chief executive officer owned 247,438 shares of the company’s stock, valued at approximately $2,170,031.26. This represents a 3.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.02% of the company’s stock.

Key Headlines Impacting Legend Biotech

Here are the key news stories impacting Legend Biotech this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and set a $50 price target (large implied upside vs. the current price), which likely attracted buying interest. Read More.
• Neutral Sentiment: HC Wainwright published forward EPS trajectories showing meaningful improvement into 2027 (examples: Q1 2027 $0.17, Q2 2027 $0.24, Q4 2027 $0.43), supporting a longer-term earnings recovery narrative even as near-term figures were revised. Read More.
• Neutral Sentiment: Coverage pieces and analyst commentaries (Globe and Mail, AmericanBankingNews) are highlighting the company alongside peers, keeping Legend in investor conversations but not introducing new material company-specific catalysts. Read More.
• Negative Sentiment: HC Wainwright trimmed near-term EPS estimates — notably Q2 2026 to $0.03 (from $0.06) and Q3 2026 to $0.07 (from $0.14) — which signals weaker near-term profitability expectations and could cap upside until results or guidance prove otherwise. Read More.

About Legend Biotech

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.